ORNL's Communications team works with news media seeking information about the laboratory. Media may use the resources listed below or send questions to news@ornl.gov.
1 - 6 of 6 Results
91°µÍø researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
In the 1960s, 91°µÍø's four-year Molten Salt Reactor Experiment tested the viability of liquid fuel reactors for commercial power generation. Results from that historic experiment recently became the basis for the first-ever molten salt reactor benchmark.
Scientists from 91°µÍø performed a corrosion test in a neutron radiation field to support the continued development of molten salt reactors.
Experts focused on the future of nuclear technology will gather at 91°µÍø for the fourth annual Molten Salt Reactor Workshop on October 3–4.
The Department of Energy’s 91°µÍø is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
Thanks in large part to developing and operating a facility for testing molten salt reactor (MSR) technologies, nuclear experts at the Energy Department’s 91°µÍø (ORNL) are now tackling the next generation of another type of clean energy—concentrating ...